We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Russia (EPICOR-RUS)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: June 15, 2011
Last Update Posted: July 11, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
EPICOR-RUS is a multi-centre, observational, prospective, longitudinal cohort study which will include patients, in a real-life setting, who are hospitalized for acute coronary syndrome (ACS) within 24 hours of symptom onset and who have a final diagnosis of Unstable Angina (UA), ST-Elevation Myocardial Infarction (STEMI) or Non-ST-Elevation Myocardial Infarction (NSTEMI). Patients will undergo clinical assessments and receive the standard medical care as determined by the treating cardiologist. Patients will not receive experimental intervention or experimental treatment as a consequence of their participation in the EPICOR-RUS observational study.

Acute Coronary Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long-tErm Follow-uP of Antithrombotic Management Patterns In Acute CORonary Syndrome Patients in RUSsia

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Short- and long-term medication and treatment prescribed by physicians in real-life setting [ Time Frame: up to 2 years ]

Secondary Outcome Measures:
  • clinical outcome (Cardiovascular events) [ Time Frame: up to 2 years ]
  • quality of life (EQ-5D questionnaire) [ Time Frame: up to 2 years ]

Enrollment: 600
Study Start Date: July 2011
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Patients hospitalized and diagnosed with UA, STEMI or NSTEMI


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Clinical Practice

Inclusion Criteria:

  • Subject must be 18 years of age or older of either gender or race
  • Diagnosis of STEMI, NSTEMI or UA confirmed using the following definitions

Exclusion Criteria:

  • UA, STEMI and NSTEMI precipitated by or as a complication of surgery, trauma, or gastrointestinal (GI) bleeding or post-Percutaneous coronary intervention (PCI).
  • UA, STEMI and NSTEMI occurring in patients already hospitalized for other reasons.
  • Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances).
  • Already included in the EPICOR-RUS study.
  • Presence of serious/severe co-morbidities in the opinion of the investigator which may limit short term (i.e. 6 month) life expectancy.
  • Current participation in a clinical trial.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01373957

Russian Federation
Research Site
Barnaul, Russian Federation
Research Site
Cheboksary, Russian Federation
Research Site
Ekaterinburg, Russian Federation
Research Site
Kazan, Russian Federation
Research Site
Kemerovo, Russian Federation
Research Site
Kirov, Russian Federation
Research Site
Krasnodar, Russian Federation
Research Site
Krasnoyarsk, Russian Federation
Research Site
Moscow, Russian Federation
Research Site
Murmansk, Russian Federation
Research Site
N.Novgorod, Russian Federation
Research Site
Novosibirsk, Russian Federation
Research Site
Petrozavodsk, Russian Federation
Research Site
Rostov-on-Don, Russian Federation
Research Site
S-Petersburg, Russian Federation
Research Site
Samara, Russian Federation
Research Site
Saratov, Russian Federation
Research site
Tomsk, Russian Federation
Research Site
Tyumen, Russian Federation
Sponsors and Collaborators
Study Director: Alexey Stepanov AstraZeneca
Principal Investigator: Mikhail Ruda RKNPK
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01373957     History of Changes
Other Study ID Numbers: NIS-CRU-XXX-2011/1
First Submitted: June 13, 2011
First Posted: June 15, 2011
Last Update Posted: July 11, 2014
Last Verified: July 2014

Keywords provided by AstraZeneca:
Acute Coronary Syndrome
antithrombotic management

Additional relevant MeSH terms:
Acute Coronary Syndrome
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases